About this session
Recent years have seen major advances in the diagnosis and treatment of Alzheimer’s disease.
New guidelines, not fully implemented yet, call for a move away from a ‘clinically’ based diagnosis to one centred on biomarkers. Specific antibodies have been identified as having the potential to significantly change management of Alzheimer’s disease in this fast-moving field.
Targeting risk factors may prevent some cases, but much less is established about managing these in people who already have the disease. A combination of disease modifying and symptomatic medication alongside non-pharmacological interventions may offer the best hope for treating patients currently.
Further research will identify more approaches that can truly revolutionise the treatment of Alzheimer’s disease. For now, understanding what is already available and how to utilise it effectively offer the best hope to people living with Alzheimer’s disease.
Free event. All are welcome. If you would like to attend, please register online no later than 48 hours prior to the event.
Book now